Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maniar

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Annals of Surgical Oncology|August 7, 2019
Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite ExperienceDaniel Solomon, Eliahu Bekhor, Natasha Leigh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2010
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangementsScott D Boyd, Bruno A Gaëta, Katherine J Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Annals of Surgical Oncology|August 7, 2019
Surveillance of Low-Grade Appendiceal Mucinous Neoplasms With Peritoneal Metastases After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Are 5 Years Enough? A Multisite ExperienceDaniel Solomon, Eliahu Bekhor, Natasha Leigh, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 25, 2010
Individual variation in the germline Ig gene repertoire inferred from variable region gene rearrangementsScott D Boyd, Bruno A Gaëta, Katherine J Jackson, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 6, 2016
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2015
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerB H O'Neil, A J Scott, W W Ma, et al.
Pageof 4